People with Graves' disease who have glutamic acid decarboxylase antibodies are just as likely to be male or female and to develop the disease at the same age as those without these antibodies.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine whether GADAb positivity consistently occurs across age and sex groups in Graves' disease, confirming generalizability.
A systematic review and meta-analysis of all published studies reporting age and sex distribution in GADAb-positive vs. GADAb-negative Graves' disease patients, including at least 1,500 patients total, with standardized antibody thresholds.
A prospective cohort could assess whether GADAb positivity emerges at similar ages and sex ratios across populations over time.
A multicenter prospective cohort following 500 newly diagnosed Graves' disease patients annually for 5 years, recording age, sex, and GADAb status at diagnosis to assess whether demographic patterns are stable.
A cross-sectional study could confirm the lack of demographic association in a larger, more diverse population.
A cross-sectional survey of 1,000 Graves' disease patients across multiple centers, measuring GADAb status and recording age and sex, with stratified analysis by region and ethnicity.
A case-control study could test whether GADAb-positive patients are selected from different demographic strata than GADAb-negative patients.
A case-control study comparing 100 GADAb-positive and 100 GADAb-negative Graves' patients, matched for age and sex, to assess whether selection bias influenced the original findings.
A case series could document rare exceptions where GADAb positivity occurs in atypical demographics.
A case series of 10 patients with Graves' disease and GADAb positivity who are male or diagnosed before age 20 or after age 70, documenting clinical course and antibody kinetics.